You just read:

Janssen Announces U.S. FDA Approval of First and Only Complete, Single-Pill, Two-Drug Regimen, JULUCA® (Dolutegravir and Rilpivirine), for the Treatment of HIV-1 Infection

News provided by

Janssen Therapeutics

Nov 21, 2017, 17:06 EST